Skip to main content

REPL

Stock
Health Care
Biotechnology

Performance overview

REPL Price
Price Chart

Forward-looking statistics

Beta
1.60
Risk
76.88%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Company info

SectorHealth Care
IndustryBiotechnology
Employees287
Market cap$485.2M

Fundamentals

Enterprise value$308.5M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity18.32

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.07
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$17M
Avg trading volume (10 day)$16M
Put-call ratio

Macro factor sensitivity

Growth-2.6
Credit+10.9
Liquidity+1.5
Inflation-6.7
Commodities-1.6
Interest Rates-0.6

Valuation

Dividend yield0.00%
PEG Ratio-3.49
Price to sales
P/E Ratio-3.49
Enterprise Value to Revenue
Price to book1.74

Upcoming events

Next earnings dayMay 22, 2025
Next dividend day
Ex. dividend day

News

REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA

The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on July 22, 2025.

Zacks Investment Research (January 22, 2025)
3 Biotech Stocks That Could Double In 12 Months

Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and analysis — of a company's pipeline, collaborations, fundamentals, key make-or-break events and cash runway — can fetch disproportionate returns.

Benzinga (March 17, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free